These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://marcqmop883179.blogofoto.com/70318116/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide